title: Resistance to inhibitors of the human immunodeficiency virus type 1 integration.
abstract: This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
authors.affiliation: State University of New York, NY, USA. daria_hazuda@merck.com
authors.forename: Daria J
authors.initials: DJ
authors.lastname: Hazuda
mesh_terms: D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000821:virology*; D019427:HIV Integrase / Q000187:drug effects / Q000235:genetics*; D019428:HIV Integrase Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology*; D006801:Humans; D016662:Virus Integration / Q000187:drug effects*
chemical_list: D019428:HIV Integrase Inhibitors; D019427:HIV Integrase